Valuation: Integrity Applications, Inc.

Market Cap 3.08M 2.69M 2.48M 2.29M 4.31M 297M 4.41M 29.68M 11.67M 145M 11.57M 11.31M 500M P/E 2024 *
-
P/E 2025 -0.12x
Enterprise Value -857K -749K -691K -637K -1.2M -82.57M -1.23M -8.26M -3.25M -40.44M -3.22M -3.15M -139M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.07%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 59 -
Director of Finance/CFO 66 27/01/2025
Chief Operating Officer - 31/01/2025
Director TitleAgeSince
Director/Board Member 59 26/08/2024
Director/Board Member 56 24/08/2023
Chairman 63 12/02/2024
Change 5-day change 1-year change 3-year change Capi.($)
+15.79%+10.00% - - 3.08M
-1.29%-3.11%-0.35%+2.64% 49.18B
+3.90%-0.39%+386.06%+588.97% 39.58B
-1.70%+4.46%+5.93%+61.54% 34.69B
-2.01%-0.76%+28.41%-8.52% 34.42B
+0.06%+0.34%+2.38%+34.47% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+72.42%+116.45% 15.36B
+1.12%+1.91%+14.54%+15.44% 14.05B
0.00%+1.36%+18.43%-31.23% 13.02B
Average +1.63%+0.03%+65.98%+97.47% 27.07B
Weighted average by Cap. -0.05%-0.18%+79.44%+122.31%

Financials

2024 2025
Net sales - -
Net income -22.6M -19.75M -18.22M -16.8M -31.66M -2.18B -32.36M -218M -85.67M -1.07B -84.86M -83M -3.67B -19.39M -16.94M -15.63M -14.41M -27.16M -1.87B -27.77M -187M -73.5M -914M -72.81M -71.21M -3.15B
Net Debt -5.35M -4.68M -4.31M -3.98M -7.5M -515M -7.66M -51.57M -20.28M -252M -20.09M -19.65M -869M -3.94M -3.44M -3.17M -2.93M -5.52M -379M -5.64M -37.95M -14.93M -186M -14.79M -14.46M -639M
Logo Integrity Applications, Inc.
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Employees
-